HC Wainwright Has Strong Estimate for DRUG FY2025 Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG) – Equities research analysts at HC Wainwright lifted their FY2025 EPS estimates for shares of Bright Minds Biosciences in a research note issued on Monday, November 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($1.84) per share for the year, up from their previous forecast of ($1.86). HC Wainwright has a “Buy” rating and a $85.00 price target on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Bright Minds Biosciences’ Q4 2025 earnings at ($0.88) EPS, Q1 2026 earnings at ($0.97) EPS, Q2 2026 earnings at ($1.28) EPS, Q3 2026 earnings at ($1.56) EPS, Q4 2026 earnings at ($1.81) EPS, FY2026 earnings at ($5.69) EPS, FY2027 earnings at ($5.79) EPS, FY2028 earnings at ($5.87) EPS, FY2029 earnings at ($1.73) EPS and FY2030 earnings at $0.59 EPS.

Bright Minds Biosciences (NASDAQ:DRUG) last announced its earnings results on Thursday, August 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.06.

A number of other research analysts have also recently weighed in on DRUG. Zacks Research raised shares of Bright Minds Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 13th. BTIG Research initiated coverage on shares of Bright Minds Biosciences in a research report on Monday, September 8th. They issued a “buy” rating and a $72.00 target price on the stock. Finally, Wall Street Zen downgraded Bright Minds Biosciences from a “hold” rating to a “sell” rating in a research report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to MarketBeat, Bright Minds Biosciences has an average rating of “Buy” and an average price target of $81.00.

Bright Minds Biosciences Price Performance

Shares of DRUG stock opened at $60.15 on Wednesday. The business’s fifty day moving average price is $55.15 and its 200 day moving average price is $39.99. Bright Minds Biosciences has a 1-year low of $23.17 and a 1-year high of $70.23. The firm has a market capitalization of $423.46 million, a PE ratio of -64.68 and a beta of -6.27.

Institutional Trading of Bright Minds Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Police & Firemen s Retirement System of New Jersey acquired a new stake in Bright Minds Biosciences during the 2nd quarter worth about $28,000. JPMorgan Chase & Co. boosted its holdings in Bright Minds Biosciences by 624.3% in the second quarter. JPMorgan Chase & Co. now owns 2,173 shares of the company’s stock worth $57,000 after purchasing an additional 1,873 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Bright Minds Biosciences during the 2nd quarter worth about $66,000. New York State Common Retirement Fund bought a new stake in Bright Minds Biosciences during the second quarter worth approximately $107,000. Finally, AdvisorShares Investments LLC boosted its holdings in shares of Bright Minds Biosciences by 28.4% during the 2nd quarter. AdvisorShares Investments LLC now owns 14,481 shares of the company’s stock worth $378,000 after buying an additional 3,200 shares during the period. 40.52% of the stock is owned by institutional investors and hedge funds.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.